(0.03%) 5 470.68 points
(0.00%) 39 111 points
(0.33%) 17 777 points
(-0.48%) $80.44
(-4.50%) $2.63
(-0.85%) $2 311.00
(0.01%) $28.87
(2.29%) $1 009.00
(0.25%) $0.936
(0.62%) $10.67
(0.45%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial...
Stats | |
---|---|
Today's Volume | 76 281 |
Average Volume | 472 941 |
Market Cap | 5.13B |
EPS | $-0.690 ( Q1 | 2024-05-09 ) |
Next earnings date | ( $-0.760 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-32.86 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.117 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-14 | Conley Emily | Sell | 5 000 | Stock Option (Right to Buy) |
2024-06-14 | Conley Emily | Buy | 5 000 | Class A Common Stock |
2024-06-14 | Conley Emily | Sell | 4 777 | Class A Common Stock |
2024-06-14 | Conley Emily | Sell | 223 | Class A Common Stock |
2024-06-12 | Flynn James E | Buy | 3 789 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-80.71 |
Last 100 transactions |
Buy: 133 880 | Sell: 1 327 400 |
Volume Correlation
Nuvalent, Inc. Correlation
10 Most Positive Correlations | |
---|---|
HURC | 0.868 |
BIMI | 0.866 |
BRZE | 0.863 |
CRBU | 0.861 |
ASUR | 0.861 |
GRPN | 0.861 |
SPRB | 0.859 |
REE | 0.854 |
ATER | 0.847 |
PDSB | 0.846 |
10 Most Negative Correlations | |
---|---|
GLNG | -0.88 |
EH | -0.876 |
PAAS | -0.862 |
CWBC | -0.861 |
RING | -0.858 |
HSON | -0.852 |
CENX | -0.844 |
CRIS | -0.835 |
USEG | -0.832 |
AMRK | -0.824 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nuvalent, Inc. Correlation - Currency/Commodity
Nuvalent, Inc. Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-2.17 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-2.17 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-1.480 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-2.87 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators